A TCR-mimic antibody to WT1 bypasses tyrosine kinase inhibitor resistance in human BCR-ABL+ leukemias

2014/04/11 by Leonid Dubrovsky, Dmitry Pankov, Elliott J. Brea +9 · 25 citations
Biochemistry, Genetics and Molecular Biology · Medicine · #Renal and related cancers #Chronic Myeloid Leukemia Treatments #Renal cell carcinoma treatment

paper · pdf · doi:10.1182/blood-2014-01-549022

Abstract

Acute and chronic leukemias, including CD34(+) CML cells, demonstrate increased expression of the Wilms tumor gene 1 product (WT1), making WT1 an attractive therapeutic target. However, WT1 is a currently undruggable, intracellular protein. ESKM is a human IgG1 T-cell receptor mimic monoclonal antibody directed to a 9-amino acid sequence of WT1 in the context of cell surface HLA-A*02. ESKM was therapeutically effective, alone and in combination with tyrosine kinase inhibitors (TKIs), against Philadelphia chromosome-positive acute leukemia in murine models, including a leukemia with the most common, pan-TKI, gatekeeper resistance mutation, T315I. ESKM was superior to the first-generation TKI, imatinib. Combination therapy with ESKM and TKIs was superior to either drug alone, capable of curing mice. ESKM showed no toxicity to human HLA-A*02:01(+) stem cells under the conditions of this murine model. These features of ESKM make it a promising nontoxic therapeutic agent for sensitive and resistant Ph(+) leukemias.

Cited by

• Building better monoclonal antibody-based therapeutics. [europepmc]
• Therapeutic bispecific T-cell engager antibody targeting the intracellular oncoprotein WT1. [europepmc]
• Structure of a TCR-Mimic Antibody with Target Predicts Pharmacogenetics. [europepmc]
• The Role of New Tyrosine Kinase Inhibitors in Chronic Myeloid Leukemia. [europepmc]
• T cell receptor mimic antibodies for cancer therapy. [europepmc]
• Activity of 8F4, a T-cell receptor-like anti-PR1/HLA-A2 antibody, against primary human AML in vivo. [europepmc]
• Opportunities and challenges for TCR mimic antibodies in cancer therapy. [europepmc]
• Optimized T-cell receptor-mimic chimeric antigen receptor T cells directed toward the intracellular Wilms Tumor 1 antigen. [europepmc]
• An immunogenic WT1-derived peptide that induces T cell response in the context of HLA-A*02:01 and HLA-A*24:02 molecules. [europepmc]
• Immune Effector Recovery in Chronic Myeloid Leukemia and Treatment-Free Remission. [europepmc]
• A therapeutic T cell receptor mimic antibody targets tumor-associated PRAME peptide/HLA-I antigens. [europepmc]
• Mechanisms of Resistance to ABL Kinase Inhibition in Chronic Myeloid Leukemia and the Development of Next Generation ABL Kinase Inhibitors. [europepmc]
• Therapeutic Antibodies against Intracellular Tumor Antigens. [europepmc]
• Therapeutic Antibodies for Myeloid Neoplasms-Current Developments and Future Directions. [europepmc]
• In Silico Analysis of the Minor Histocompatibility Antigen Landscape Based on the 1000 Genomes Project. [europepmc]
• ALK and RET Inhibitors Promote HLA Class I Antigen Presentation and Unmask New Antigens within the Tumor Immunopeptidome. [europepmc]
• Chronic myeloid leukemia-from the Philadelphia chromosome to specific target drugs: A literature review. [europepmc]
• T-cell receptor mimic (TCRm) antibody therapeutics against intracellular proteins. [europepmc]
• T-Cell Receptor Mimic Antibodies for Cancer Immunotherapy. [europepmc]
• Targeting intracellular WT1 in AML with a novel RMF-peptide-MHC-specific T-cell bispecific antibody. [europepmc]
• A Conformation Selective Mode of Inhibiting SRC Improves Drug Efficacy and Tolerability. [europepmc]
• Emerging new therapeutic antibody derivatives for cancer treatment. [europepmc]
• Molecular Aspects of Resistance to Immunotherapies-Advances in Understanding and Management of Diffuse Large B-Cell Lymphoma. [europepmc]
• Validation and promise of a TCR mimic antibody for cancer immunotherapy of hepatocellular carcinoma. [europepmc]
• The Interplay between T Cells and Cancer: The Basis of Immunotherapy. [europepmc]

Related

• Targeting of acute myeloid leukemia by five-gene engineered T cells expressing transgenic T-cell receptor specific to WT1, chimeric antigenic receptor specific to GM-CSF receptor, bispecific T-cell engager specific to CD33, and tEGFR suicide gene system
• Development of CAR T cells Targeting a Surface RNA Binding Protein for the Treatment of Acute Leukemias
• Preclinical assessment of MAGE-A4-specific TCR-NK cells against solid tumors
• T cells dressed up with a dual HLA-restricted TCR targeting cathepsin G drive effective AML eradication
• Small Molecule Modulation of MHC-I Surface Expression: A Click Chemistry-Based Discovery Approach